Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2022 · 10-Q
Revenue—
Net Income$577.23K$577.23K−96.3% vs Q3 2021 EPS Diluted$0.00$0.00— vs Q3 2021 Operating Cash Flowderived-$165,341N/M Free Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
derived
ended Sep 30, 2022 · filed Nov 21, 2022 · 52 d after period end